Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study

被引:5
作者
Mohan, Anjana [1 ]
Majd, Zahra [1 ]
Trinh, Trang [1 ]
Paranjpe, Rutugandha [1 ]
Abughosh, Susan M. [1 ]
机构
[1] Univ Houston, Dept Pharmaceut Hlth Outcomes & Policy, Coll Pharm, 4849 Calhoun Rd Suite 4050, Houston, TX 77204 USA
关键词
Adherence; Atrial fibrillation; Drug-drug interactions; Direct oral anticoagulants; Warfarin; MOTIVATIONAL INTERVIEWING INTERVENTION; DRUG-DRUG INTERACTIONS; OLDER-ADULTS; WARFARIN; STATINS; ASSOCIATION; RIVAROXABAN; AMIODARONE; DABIGATRAN; MANAGEMENT;
D O I
10.1007/s11096-022-01417-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Poor adherence to oral anticoagulants is a significant problem in atrial fibrillation (AF) patients with comorbidities as it increases the risk for cardiac and thromboembolic events. Aim The primary objective was to evaluate adherence to direct oral anticoagulants (DOACs) or warfarin using group-based trajectory modeling (GBTM). The secondary objective was to identify the predictors of adherence to oral anticoagulants. Finally, to report the drug interactions with DOACs/warfarin. Method This retrospective study was conducted among continuously enrolled Medicare Advantage Plan members from January 2016-December 2019. AF patients with comorbid hypertension, diabetes and hyperlipidemia using warfarin/DOACs were included. Monthly adherence to DOAC/warfarin was measured using proportion of days covered (PDC) and then modeled in a logistic GBTM to identify the distinct patterns of adherence. Logistic regression model was conducted to identify the predictors of adherence to oral anticoagulants adjusting for all baseline characteristics. Concomitant use of DOACs/warfarin with CYP3A4,P-gp inhibitors were measured. Results Among 317 patients, 137 (43.2%) and 79 (24.9%) were DOAC, and warfarin users, respectively. The adherence trajectory model for DOACs included gradual decline (40.4%), adherent (38.8%), and rapid decline (20.8%). The adherence trajectories for warfarin adherence included gradual decline (8.9%), adherent (59.4%), and gaps in adherence (21.7%). Predictors of adherence included type of oral anticoagulant, stroke risk score, low-income subsidy, and baseline PDC. CYP3A4,P-gp drugs were co-administered with DOACs /warfarin resulting in adverse events. Conclusion Adherence to oral anticoagulants is suboptimal. Interventions tailored according to past adherence trajectories may be effective in improving patient's adherence.
引用
收藏
页码:966 / 974
页数:9
相关论文
共 37 条
[1]   Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence [J].
Abughosh, Susan M. ;
Vadhariya, Aisha ;
Johnson, Michael L. ;
Essien, E. James ;
Esse, Tara W. ;
Serna, Omar ;
Gallardo, Esteban ;
Boklage, Susan H. ;
Choi, Jeannie ;
Holstad, Marcia M. ;
Fleming, Marc L. .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10) :1053-1062
[2]   Association between Cerebral Infarction Risk and Medication Adherence in Atrial Fibrillation Patients Taking Direct Oral Anticoagulants [J].
Akagi, Yuuki ;
Iketaki, Akiko ;
Nakamura, Reiko ;
Yamamura, Shigeo ;
Endo, Minori ;
Morikawa, Keisuke ;
Oikawa, Shun ;
Ohta, Takahiro ;
Tatsumi, Shimpei ;
Suzuki, Takafumi ;
Mizushima, Atsuhiro ;
Koido, Keiichi ;
Takahashi, Tatsuya .
HEALTHCARE, 2021, 9 (10)
[3]   Long-Term Medication Adherence Trajectories to Direct Oral Anticoagulants and Clinical Outcomes in Patients With Atrial Fibrillation [J].
An, Jaejin ;
Bider, Zoe ;
Luong, Tiffany Q. ;
Cheetham, T. Craig ;
Lang, Daniel T. ;
Fischer, Heidi ;
Reynolds, Kristi .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (21)
[4]  
[Anonymous], CIGNA WHAT IS MEDICA
[5]   Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration [J].
Borne, Ryan T. ;
O'Donnell, Colin ;
Turakhia, Mintu P. ;
Varosy, Paul D. ;
Jackevicius, Cynthia A. ;
Marzec, Lucas N. ;
Masoudi, Frederick A. ;
Hess, Paul L. ;
Maddox, Thomas M. ;
Ho, P. Michael .
BMC CARDIOVASCULAR DISORDERS, 2017, 17
[6]   Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation [J].
Chang, Shang-Hung ;
Chou, I-Jun ;
Yeh, Yung-Hsin ;
Chiou, Meng-Jiun ;
Wen, Ming-Shien ;
Kuo, Chi-Tai ;
See, Lai-Chu ;
Kuo, Chang-Fu .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (13) :1250-1259
[7]  
Charlton A, 2021, J MANAG CARE SPEC PH, V27, P1210, DOI 10.18553/jmcp.2021.27.9.1210
[8]   Bleeding as an Outcome Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population [J].
Deitelzweig, Steven B. ;
Pinsky, Brett ;
Buysman, Erin ;
Lacey, Michael ;
Makenbaeva, Dinara ;
Wiederkehr, Daniel ;
Graham, John .
CLINICAL THERAPEUTICS, 2013, 35 (10) :1536-1545
[9]   Group-Based Trajectory Models: Assessing Adherence to Antihypertensive Medication in Older Adults in a Community Pharmacy Setting [J].
Dillon, Paul ;
Stewart, Derek ;
Smith, Susan M. ;
Gallagher, Paul ;
Cousins, Grainne .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (06) :1052-1060
[10]   Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial [J].
Flaker, Greg ;
Lopes, Renato D. ;
Hylek, Elaine ;
Wojdyla, Daniel M. ;
Thomas, Laine ;
Al-Khatib, Sana M. ;
Sullivan, Renee M. ;
Hohnloser, Stefan H. ;
Garcia, David ;
Hanna, Michael ;
Amerena, John ;
Harjola, Veli-Pekka ;
Dorian, Paul ;
Avezum, Alvaro ;
Keltai, Matyas ;
Wallentin, Lars ;
Granger, Christopher B. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (15) :1541-1550